562. Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.
作者: Peter Hanlon.;Elaine Butterly.;Lili Wei.;Heather Wightman.;Saleh Ali M Almazam.;Khalid Alsallumi.;Jamie Crowther.;Ryan McChrystal.;Heidi Rennison.;Katherine Hughes.;Jim Lewsey.;Robert Lindsay.;Stuart McGurnaghan.;John Petrie.;Laurie A Tomlinson.;Sarah Wild.;Amanda Adler.;Naveed Sattar.;David M Phillippo.;Sofia Dias.;Nicky J Welton.;David A McAllister.
来源: JAMA. 2025年333卷12期1062-1073页
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex.
564. Testicular Germ Cell Tumors: A Review.
作者: Nirmish Singla.;Aditya Bagrodia.;Ezra Baraban.;Christian D Fankhauser.;Yasser M A Ged.
来源: JAMA. 2025年333卷9期793-803页
Testicular cancer is the most common solid malignancy among males aged 15 to 40 years in the US, with approximately 10 000 new cases diagnosed each year. Between 90% and 95% of testicular cancers are germ cell tumors (GCTs).
|